The prognosis of grade group 1 prostate cancer varies widely, with high-risk features increasing the possibility of adverse pathology, biochemical recurrence, and in some cases, death. Gleason grade ...

Dr. Neal Patel says biopsy results may not fully capture prostate cancer risk, stressing that PSA, stage and disease volume should also guide treatment. Biopsy results alone may not fully capture the ...

foley catheter leads to TULIP Proposed 5-tiered system found to predict the risk of prostate cancer-specific mortality. A proposed simpler grading system for prostate cancer (PCa) can predict the risk ...

New research highlights the challenge of balancing the risks of overdiagnosing and underdiagnosing prostate cancer early enough to intervene and minimize risk of death. Recently, some experts have ...

A new 18-gene urine test demonstrated higher diagnostic accuracy for high-grade prostate cancer compared with existing biomarker tests, a study showed. In applying a testing approach with 95% ...

Researchers at the University of Michigan Rogel Cancer Center have developed a new urine-based test that addresses a major problem in prostate cancer: how to separate the slow-growing form of the ...

A new study reveals that some men who are diagnosed with "Grade Group one" (GG1) prostate cancer may actually be at higher risk than biopsy results suggest, according to research led by Weill Cornell ...

Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later ...

Former President Joe Biden has been diagnosed with an "aggressive" form of prostate cancer that has spread to his bones. But what does it mean for this type of cancer to be called aggressive? As a ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

National guidelines on prostate cancer screening with the PSA test are set by the US Preventive Services Task Force. Marc B. Garnick, the Gorman Brothers Professor of Medicine at Harvard Medical ...